240 related articles for article (PubMed ID: 36113330)
1. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
2. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
3. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
4. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
5. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
6. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy.
Liu S; Wu J; Feng Y; Guo X; Li T; Meng M; Chen J; Chen D; Tian H
Bioact Mater; 2023 Apr; 22():211-224. PubMed ID: 36246666
[TBL] [Abstract][Full Text] [Related]
7. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger.
Hu Y; Lin L; Chen J; Maruyama A; Tian H; Chen X
Biomaterials; 2020 Sep; 252():120114. PubMed ID: 32422491
[TBL] [Abstract][Full Text] [Related]
8. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
[TBL] [Abstract][Full Text] [Related]
9. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
10. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
11. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
12. Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
Kim Y; Kang S; Shin H; Kim T; Yu B; Kim J; Yoo D; Jon S
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14628-14638. PubMed ID: 32430981
[TBL] [Abstract][Full Text] [Related]
13. A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy.
Zhao J; Xu Y; Ma S; Wang Y; Huang Z; Qu H; Yao H; Zhang Y; Wu G; Huang L; Song W; Tang Z; Chen X
Adv Mater; 2022 Mar; 34(10):e2109254. PubMed ID: 34984753
[TBL] [Abstract][Full Text] [Related]
14. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
[TBL] [Abstract][Full Text] [Related]
15. Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination.
Lv X; Huang J; Min J; Wang H; Xu Y; Zhang Z; Zhou X; Wang J; Liu Z; Zhao H
J Control Release; 2023 May; 357():109-119. PubMed ID: 36738971
[TBL] [Abstract][Full Text] [Related]
16. In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy.
Li X; Zhang Y; Wu X; Chen J; Yang M; Ma F; Shi L
Small; 2022 Aug; 18(32):e2203100. PubMed ID: 35843873
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
18. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
19. Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy.
Gao ZL; Xu W; Zheng SJ; Duan QJ; Liu R; Du JZ
Nano Lett; 2023 Mar; 23(5):1904-1913. PubMed ID: 36801829
[TBL] [Abstract][Full Text] [Related]
20. A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy.
Lu Z; Zhang Y; Wang Y; Tan GH; Huang FY; Cao R; He N; Zhang L
J Control Release; 2021 Apr; 332():245-259. PubMed ID: 33647430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
